6VPY

I33M (I3.2 mutant from CH103 Lineage)

Summary for 6VPY

• Entry DOI: 10.2210/pdb6vpy/pdb
• Descriptor: I33M light chain, I33M heavy chain, CHLORIDE ION, ... (5 entities in total)
• Functional Keywords: fab fragment, hiv-1, antibody, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 4
• Total formula weight: 95393.29

Authors

Fera, D.,Zhou, J. (deposition date: 2020-02-04, release date: 2020-07-15, Last modification date: 2024-10-09)

Primary citation

Zhou, J.O.,Zaidi, H.A.,Ton, T.,Fera, D.
The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage.
Front Immunol, 11:1529-1529, 2020

PubMed Abstract: Understanding affinity maturation of antibodies that can target many variants of HIV-1 is important for vaccine development. While the antigen-binding site of antibodies is known to mutate throughout the co-evolution of antibodies and viruses in infected individuals, the roles of the mutations in the antibody framework region are not well understood. Throughout affinity maturation, the CH103 broadly neutralizing antibody lineage, from an individual designated CH505, altered the orientation of one of its antibody variable domains. The change in orientation was a response to insertions in the variable loop 5 (V5) of the HIV envelope. In this study, we generated CH103 lineage antibody variants in which residues in the variable domain interface were mutated, and measured the binding to both autologous and heterologous HIV-1 envelopes. Our data show that very few mutations in an early intermediate antibody of the lineage can improve binding toward both autologous and heterologous HIV-1 envelopes. We also crystallized an antibody mutant to show that framework mutations alone can result in a shift in relative orientations of the variable domains. Taken together, our results demonstrate the functional importance of residues located outside the antigen-binding site in affinity maturation.

PubMed: 32765530
DOI: 10.3389/fimmu.2020.01529

Experimental method

X-RAY DIFFRACTION (2.36 Å)